Centre of Evidence of Dermatology Best practice guidelines

Guidelines chronic spontaneous urticaria Updated on december 2019


The information provided by this website comes from sources deemed reliable. However, the French Dermatology Society recommends that the user ensure the validity of this information. Some may prove to be erroneous or be subject to typos or display errors.

The use of this data is under the sole responsibility of the user. The French Dermatology Society cannot be blamed for a misinterpretation of the data provided by the site, or in the event of erroneous information. This decision tree and all the contents of this site have been developed in the context of updated data from science according to the HAS methodology, expert opinions and reviewers of the various documents and in the context of the French healthcare system.

Adult and adolescent > 12 years
Stage 1 / first-line treatment

Back to decision-making tree Print last updated on 18/09/2020

Second-generation anti-H1 antihistamines
single dose per day

Second-generation anti-H1 antihistamines at conventional dose (single dose, MA-compliant) are effective and well tolerated.

They are therefore the first-line treatment in CSU.
There are few reasons to prefer one molecule over another.

Experts recommend taking this medication in the evening, because of the risk of drowsiness and to avoid night-time flare-ups.

  • Was this article helpful to you?
  • Your opinion counts!

    This notice will not be published on this site, but only sent to the publication management. Your email will only be used to reply to you if we deem it necessary. No response will be sent to any request for medical advice via this form.

stage 2 if failure of anti-H1 antihistamines

Centre of Evidence of Dermatology Centre of Evidence of Dermatology logo
10 cité Malesherbes
Work +33.1 43 27 01 56
Fax +33.1 43 27 01 86